Xvivo Perfusion AB AI Stock Analysis
Want to see SE:XVIVO full AI Analyst Report?
Xvivo Perfusion AB (XVIVO) AI Stock Analysis
Xvivo Perfusion AB
(Nasdaq OMX AB:XVIVO)
The score is driven primarily by solid fundamentals—especially a very strong, low-debt balance sheet and improved recent profitability/cash generation—plus a constructive earnings call highlighting strong growth and regulatory progress. These positives are meaningfully offset by weak technicals (price below key moving averages with negative MACD) and a demanding valuation (P/E ~50), alongside near-term execution risks (component constraints, services weakness, and expected margin pressure from planned investment).
Xvivo Perfusion AB (XVIVO) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 598.49M
- Dividend Yield
- ―
- Average Volume (3M)
- 80.72K
- Price to Earnings (P/E)
- 48.2
- Beta (1Y)
- 1.25
- Revenue Growth
- 17.83%
- EPS Growth
- 330.94%
- Country
- Sweden
- Employees
- 207
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Devices
Xvivo Perfusion AB Business Overview & Revenue Model
Company Description
Xvivo Perfusion AB (publ) is a medical technology company that creates and supplies advanced solutions for the preservation and perfusion of organs, tissues, and cells, primarily for use in transplantation. The company's global reach extends across S...
How the Company Makes Money
XVIVO primarily makes money by selling transplantation-related products to healthcare customers involved in organ transplantation (e.g., transplant centers, hospitals, and organ procurement-related organizations). Key revenue streams include: (1) sal...
Xvivo Perfusion AB Earnings Call Summary
The call was strongly positive overall, with 32% organic Q3 growth, improving EBITDA and cash flow, strong thoracic and heart momentum, major European and U.S. regulatory progress, and multiple expansion opportunities. The main challenges were temporary component and manufacturing-transfer constraints, weaker services revenue and margins, uncertainty around a major U.S. lung customer, reimbursement timing in Europe, competition in U.S. Liver, and planned near-term commercial investment that is expected to cause a slight margin dip.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management said kidney growth would be “moderate growth, probably around 30%” next year, although component shortages mean XVIVO “will not be able to fulfill the full demand of the market next year in kidney,” with growth expected to “return to higher levels of growth from the beginning of 2027”; service growth in 2027 is “very reasonable to expect,” “not necessarily in Q4”; new lung customer growth will “hopefully cover any shortfall,” which is the “working hypothesis right now”; static cold storage growth is expected to be “roughly 5% for next year”; Tier 2 heart customers are targeted for onboarding in December, with a “three to four months” listing process; the U.S. Heart Assist Transport commercial launch is targeted for “late 2027,” subject to the FDA review process and approval; Liver Assist is targeted for a 510(k) submission in “the first half of 2027” and a commercial launch in “early 2028,” subject again to regulatory timelines; and management expects “a slight margin dip during the second half of the year” from increased sales-force investment.
Xvivo Perfusion AB Financial Statement Overview
Summary
Strong balance sheet (very low leverage with ~0.06 debt-to-equity) and improved TTM profitability and cash conversion support the score. Offsetting this, profitability has been volatile (notable margin step-down from 2024 levels) and free cash flow consistency remains a concern after multiple prior years of negative FCF.
Income Statement
78PositiveBalance Sheet
87Very PositiveCash Flow
62Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 958.65M | 812.16M | 822.41M | 597.54M | 415.29M | 258.39M |
| Gross Profit | 614.41M | 533.50M | 616.41M | 445.11M | 296.96M | 188.28M |
| EBITDA | 214.12M | 153.14M | 272.97M | 35.05M | 65.58M | 39.20M |
| Net Income | 128.85M | 25.16M | 172.18M | 91.82M | 18.43M | 8.15M |
Balance Sheet | ||||||
| Total Assets | 2.59B | 2.37B | 2.40B | 2.20B | 1.73B | 1.54B |
| Cash, Cash Equivalents and Short-Term Investments | 313.24M | 292.09M | 415.52M | 546.09M | 246.54M | 398.70M |
| Total Debt | 120.61M | 124.72M | 34.04M | 31.44M | 10.01M | 5.72M |
| Total Liabilities | 323.02M | 260.65M | 245.97M | 250.57M | 302.95M | 257.15M |
| Stockholders Equity | 2.27B | 2.11B | 2.16B | 1.95B | 1.43B | 1.29B |
Cash Flow | ||||||
| Free Cash Flow | 191.56M | -151.84M | -81.86M | -97.65M | -103.09M | -106.13M |
| Operating Cash Flow | 268.77M | 101.07M | 111.29M | 46.29M | 27.86M | -12.06M |
| Investing Cash Flow | -237.79M | -258.41M | -243.81M | -161.62M | -197.62M | -187.70M |
| Financing Cash Flow | -11.14M | 72.25M | -10.90M | 418.55M | -6.84M | 234.61M |
Xvivo Perfusion AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XVIVO, the sentiment is Negative. The current price of 197.20 is below the 20-day moving average (MA) of 202.56, below the 50-day MA of 219.58, and below the 200-day MA of 242.84, indicating a bearish trend. The MACD of -6.18 indicates Negative momentum. The RSI at 38.49 is Neutral, neither overbought nor oversold. The STOCH value of 24.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:XVIVO.
Xvivo Perfusion AB Peers Comparison
Overall Rating
SE:GETI.B67Neutral
SE:XVIVO64Neutral
SE:VITR63Neutral
SE:SEDANA49Neutral
SE:BICO40Underperform
SE:SCIB40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 67Neutral | SEK 75.72B | 26.76 | 9.13% | 1.71% | -3.90% | 37.73% | |
| 64Neutral | SEK 6.21B | 48.22 | 5.89% | ― | 17.83% | 330.94% | |
| 63Neutral | SEK 15.94B | -3.21 | -61.57% | 0.93% | -1.94% | -1223.74% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 49Neutral | SEK 883.11M | -25.59 | -3.88% | ― | 0.42% | 15.03% | |
| 40Underperform | SEK 1.10B | -5.05 | -28.59% | ― | -5.27% | 34.38% | |
| 40Underperform | SEK 128.49M | -0.68 | -415.20% | ― | 54.94% | 47.64% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:XVIVO | Xvivo Perfusion AB | 197.20 | 31.60 | 19.08% | |
| SE:GETI.B | Getinge AB (UK) | 278.00 | 76.35 | 37.86% | |
| SE:VITR | Vitrolife AB | 117.70 | -22.75 | -16.20% | |
| SE:BICO | BICO Group AB Class B | 16.30 | -2.01 | -10.98% | |
| SE:SCIB | SciBase Holding AB | 9.10 | -9.99 | -52.34% | |
| SE:SEDANA | Sedana Medical AB | 8.89 | -0.74 | -7.68% |
Xvivo Perfusion AB Corporate Events
Xvivo Perfusion Boosts Sales and Profit as Heart R&D Spend Rises
Xvivo Perfusion AB reported robust third-quarter 2026 performance, with net sales rising 34 percent to SEK 252.6 million driven by 32 percent organic growth in local currencies. Thoracic and abdominal product sales saw strong double-digit increases,...
XVIVO Perfusion Sets October 22 Call for Q3 2026 Interim Report
XVIVO Perfusion AB has scheduled a conference call to discuss its interim report for the July–September 2026 period, reinforcing its communication with investors and analysts in the transplantation-focused medtech sector. The presentation, led by CEO...
XVIVO Perfusion Sets 2027 Nomination Committee and Invites Shareholder Input
The following members have been appointed to XVIVO Perfusion’s nomination committee ahead of the 2027 annual general meeting: Henrik Blomquist, representing Bure Equity AB; Thomas Ehlin, representing The Fourth Swedish National Pension Fund; Martin L...
XVIVO Files FDA PMA for Heart Assist Transport System After Key U.S. Trial
XVIVO Perfusion AB has submitted a Premarket Approval application to the U.S. Food and Drug Administration for its XVIVO Heart Assist Transport System, supported by data from the 141-patient PRESERVE IDE trial at 14 leading U.S. heart transplant cent...
XVIVO Wins CE Mark for Heart Preservation System, Expanding European Transplant Access
XVIVO Perfusion has secured CE certificates for its XVIVO Heart Assist Transport system, a hypothermic oxygenated perfusion-based technology designed to preserve donor hearts in an oxygen-rich, controlled environment. This approval makes the system i...
XVIVO Wins Expanded U.S. Enrollment for Heart Transport Trial
XVIVO Perfusion AB has secured U.S. regulatory clearance to enroll an additional 60 patients in the PRESERVE Continued Access Protocol study for its investigational XVIVO Heart Assist Transport device, following completion of the initial cohort acros...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 24, 2026
